By Zeba Siddiqui MUMBAI (Reuters) – Dr Reddy’s Laboratories Ltd, India’s second-largest drugmaker by sales, said on Friday it has received a “warning letter” from the U.S. Food and Drug Administration over what the regulator has deemed inadequate quality control procedures at three manufacturing plants in southern India. The warning letter means Dr Reddy’s will not receive FDA approvals to sell drugs manufactured at the plants for now, a blow for business at a company which relies on the United States for a majority of its sales. The plants make a significant contribution to company sales, with one alone accounting for 10-12 percent, Dr Reddy’s said.
Read the rest here:
India’s Dr Reddy’s gets FDA warning on three drug plants